Yang Xia, Ye Xin, Lin Zhengyu, Jin Yong, Zhang Kaixian, Dong Yuting, Yu Guohua, Ren Haipeng, Fan Weijun, Chen Jin, Lin Qingfeng, Huang Guanghui, Wei Zhigang, Ni Yang, Li Wenhong, Han Xiaoying, Meng Min, Wang Jiao, Li Yuliang
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Department of Interventional Therapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
J Cancer Res Ther. 2018;14(4):764-771. doi: 10.4103/jcrt.JCRT_269_18.
The purpose of the study is to retrospectively evaluate the safety and efficacy of microwave ablation (MWA) for the treatment of ground-glass opacity (GGO)-lung adenocarcinoma.
From December 2013 to June 2017, a total of 51 patients (22 males and 29 females, mean age of 69.4 ± 10.1 years) were included in this study, with 51 lung adenocarcinoma lesions showing GGO (mean long-axis diameter of 18.7 ± 6.05 mm). They received a total of 52 sessions of percutaneous computed tomography-guided (CT-guided) MWA. First, lung adenocarcinoma with GGO was histologically defined by needle biopsy under the guidance of CT. Second, the efficacy of CT-guided MWA was analyzed, including the feasibility, safety, 3 years local progression-free survival (LPFS), 3 years disease-specific survival, and 3 years overall survival (OS). Final, complications after MWA were also summarized.
The technical success rate was 100%, without MWA procedure-related death. At the median follow-up period (27.02, range: 7-45 months), the rates of 3 years LPFS, cancer-specific survival, and OS were 98%, 100%, and 96%, respectively. The complications after MWA included pneumothorax (48.1%, 25/52), hemoptysis (28.8%, 14/52), pleural effusion (23.1%, 12/52), and pulmonary infection (7.7%, 4/52).
CT-guided percutaneous MWA was a feasible, safe, and effective therapeutic approach for treating GGO-lung adenocarcinoma.
本研究旨在回顾性评估微波消融（MWA）治疗磨玻璃密度影（GGO）型肺腺癌的安全性和有效性。
2013年12月至2017年6月，本研究共纳入51例患者（男性22例，女性29例，平均年龄69.4±10.1岁），51个肺腺癌病灶表现为GGO（平均长径18.7±6.05mm）。他们共接受了52次经皮计算机断层扫描引导（CT引导）的MWA治疗。首先，在CT引导下通过穿刺活检对GGO型肺腺癌进行组织学定义。其次，分析CT引导下MWA的疗效，包括可行性、安全性、3年局部无进展生存期（LPFS）、3年疾病特异性生存率和3年总生存期（OS）。最后，总结MWA后的并发症。
技术成功率为100%，无MWA手术相关死亡。在中位随访期（27.02，范围：7 - 45个月），3年LPFS、癌症特异性生存率和OS分别为98%、100%和96%。MWA后的并发症包括气胸（48.1%，25/52）、咯血（28.8%，14/52）、胸腔积液（23.1%，12/52）和肺部感染（7.7%，4/52）。
CT引导下经皮MWA是治疗GGO型肺腺癌的一种可行、安全且有效的治疗方法。
